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Objective(s): Specific risk assessment models have been developed for
bariatric and colorectal procedures. A similar instrument, specific for patients
with critical limb ischemia (CLI), could improve patient-centered clinical
decisionmaking.We describe a novel tool to predict 30-daymajormorbidity
and mortality (M&M) after bypass surgery for CLI.
Methods: The 2007-2009 National Surgical Quality Improvement
Program patient data (N  4894) were analyzed to test 32 preoperative
factors for association with 30-day M&M. Significant predictors in multi-
variate models were assigned integer values (points), which were added to
calculate a patient’s comprehensive risk assessment for bypass (CRAB) score.
Performance was assessed (C-index) and compared with other tools (Amer-
ican Society of Anesthesiologists class, Surgical Risk Scale, and Prevent III
score) on a distinct validation sample of 1620 individuals.
Results:Overall, 921 patients (18.8%) suffered major morbidity and 144
(2.9%) died. The CRAB model included seven predictors of 30-day M&M
(Table). Applied to the validation sample, the CRAB score accurately predicted
morbidity and mortality rates: 14% and 1%, respectively, in low-risk patients
(CRAB2) vs 22% and 6% (CRAB 3-4) vs 31% and 15% in high-risk patients
(CRAB 5; P  .001). Accuracy of CRAB mortality prediction (C-index 
.76, P  .001) exceeded American Society of Anesthesiologists class (0.59),
Surgical Risk Scale (0.6), and Prevent III score (0.65). CRAB was the only
model to predict morbidity at a statistically significant level (P .01).
Conclusions: The CRAB is the first targeted risk assessment instrument
formorbidity andmortality after bypass surgery inCLI patients. The assessment
uses clinically relevant factors and a straightforward scoring system, it is superior
to other generalmodels for predictionofmortality, and is the only instrument to
predict major morbidity. This unique tool provides an evidence basis for patient-
centered clinical decision-making, andmay have a role at identifying patients at the
highest risk for surgery in whom an endovascular approach is preferable.
Table. CRAB score
Variable Points AOR (95% CI) P
Age 75 years 1 1.31 (1.09-1.59) .004
Dialysis dependence 1 1.49 (1.14-1.93) .003
Agnina within 6 months 1 1.54 (1.1-2.25) .02
Prior extremity
revascularization 1 1.42 (1.18-1.70) .001
Obesity 1 1.53 (1.26-1.86) .001
Emergency surgery 2 2.15 (1.42-3.25) .001
Functional dependence
Partial 2 1.79 (1.47-2.19) .001
Total 3 2.37 (1.34-4.17) .003
Total maximum points 10
AOR, Adjusted odds ratio; CI, confidence interval.
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Objective(s): This study is a review and evaluation of twomodalities of
revascularization for patients with critical limb ischemia—endovascular
(EV) and conventional bypass (CB) surgery—to identify efficacy and cost-
effectiveness by comparing reintervention rate, amputation rate, and total
cost to hospital in this particular group.
Methods: Retrospective review was performed for 214 cases in 192
patients with diagnosis of critical limb ischemia requiring revascularization
between 2007 and 2011. We evaluated reintervention rate and amputation
rate at 1, 3, 6, 12, and36months in primary EV vs CB surgery groups. The
total cost to the hospital was also compared in these groups.
Results: Between July 2007 and June 2011, Conemaugh Physicians
Group Vascular Surgery Department treated 214 limbs in 192 patients with
diagnosis of critical limb ischemia. CB surgery using vein graft was per-
formed in 84 limbs (39.3%), and EV primary revascularization, including
atherectomy, balloon angioplasty, and stent placement, was performed in
130 limbs (60.7%). The cumulative amputation rate in both groups was
13.1% at 36 months, of which 8.8% (19 limbs) were in the EV group, and
4.2% (nine limbs) were in the CB group (P  .671). The amputation rate
was 2.3%, 9.2%, 11.5%, 13%, and 14.5% in the EV group and 3.6%, 6%, 7.2%,
8.4%, 9.6%, and 10.8% in the CB group, respectively, at 1, 3, 6, 12, 24, and 36
months. The cumulative secondary intervention rate in both groups was 24% at
36 months. Of these, 12.6% were in the EV group and 11.7% were in the CB
group (P  .940). Secondary intervention rates were 5.4%, 10.8%, 14.6%,
19.2%, 20.0%, 20.9% in the EV group and 8.3%, 15.5%, 21.4%, 27.4%, 28.6%,
and 29.7% in the CB group at 1, 3, 6, 12, 24, and 36 months, respectively.
During 36 months of follow-up, more than two interventions for limb salvage
were required in 4.6% in the EV and in 8.3% in the CB group (P .268). Total
cost to the hospital for the first intervention was $27,365.03  $18,916.34
(range, $3,018-$119,518) in the EV group and $24,727.99 14,373.89
(range, $6,570-$70,282) in the CB groups (P .292).
Conclusions: In our experience, EV revascularization is as effective for
limb salvage and cost-effective as CB for the primary treatment of critical
limb ischemia.
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Objective(s): Endovascular treatment (endoRx) is often used as the
initial treatment for critical limb ischemia. The goal of this study was to
examine the likelihood, predictors, and outcomes of open surgical (OS)
revascularization or reintervention after initial endoRx for critical limb
ischemia.
Methods: We retrospectively reviewed a prospectively collected data-
base from January 1, 2007, to December 31, 2010. Demographics, Ruth-
erford classification, prior procedures, secondary endoRx, and limb salvage
rates were analyzed. Statistical significance was determined by 2 and mul-
tivariate regression analysis with P  .025.
Results: Of the 302 study patients, 126 (41%) had initial OS; 158
(52%) had initial endoRx; and 21 (7%) had hybrid procedures. Of the 126
patients treated by initial OS, 57 (45%) required a secondary endoRx. Of the
158 patients who initially underwent endoRx, 71 (45%) required a second-
ary OS. Compared with those who were treated by initial OS, patients who
had OS after failed endoRx had worse limb salvage rates (odds ratio, 1.6;
95% confidence interval, 0.215-0.894, P  .023). A similar outcome was
seen in those who required repeat endoRx after a failed initial endoRx (odds
ratio, 1.25; 95% confidence interval, 0.104-0.505, P .0001). Diabetes and
tissue loss predicted need for OS after initial endoRx. Only diabetes pre-
dicted the need for repeated endoRx after a failed initial attempt. Overall
amputation rate was 14.9%. Renal failure and initial endoRx were predictors
of major amputation when controlling for all potential confounders.
Conclusions: Patients who require open OS revascularization or re-
peated endoRx after initial endoRx for CLI have worse limb salvage rates
than patients who undergo initial OS revascularization. Therefore, in select
patients in whom an appropriate surgical option exists, OS revascularization
should be considered as the initial therapy for critical limb ischemia.
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Objective(s): The number of patients aged80 years undergoing treat-
ment of symptomatic advanced femoropopliteal disease is increasing. This study
examined the clinical efficacy of these interventions in this specific population.
Methods: A database of patients undergoing open (OPEN) and endo-
luminal (ENDO) intervention for TransAtlantic Inter-Society Concensus
(TASC) II C and D femoropopliteal lesions between 1990 and 2010 was
retrospectively queried. Patients aged 80 years were selected. Kaplan-
Meier survival analyses were performed to assess time-dependent outcomes.
Factor analyses were performed using a Cox proportional hazard model for
time dependent variables.
Results: During the 20-year period, 2539 patients underwent OPEN
or ENDO treatment for symptomatic and anatomically advanced femoro-
popliteal disease (TASC II C and D); of these, 353 (14%) were aged 80
years (Table). There was a significant difference in the ages and modified
cardiac risk index between the two groups, with older and more high risk
patients undergoing ENDO. The groups had equivalent comorbidities and
survival. OPEN was more commonly performed on those with rest pain/
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